Y-mAbs Therapeutics, Inc.

Immunotherapies for Life

Press Releases

YmAbs Granted Rare Pediatric Disease Designation for hu3F8 Antibody

Burtomab Receives Breakthrough Therapy Designation for advanced form of pediatric cancer

YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

YmAbs Announces Acceptance of Presentations of Burtomab Data at ASCO 2017 Annual Meeting

YmAbs’ 131I-8H9 Receives EU Orphan Drug Designation

YmAbs Raises $12 Million in Equity Funding

YmAbs to Present Company Overview at the 35th Annual J.P. Morgan Healthcare Conference 2017

Priority Review Program Extended Through 2022

Y-mAbs Granted Rare Pediatric Disease Designation for Radiolabeled 124I-8H9 antibody

Clinical Pipeline Highlights

Product	Indication	Development Phase
		Pre-clin Phase I Phase I/II Phase II Phase III
Burtomab 131I-8H9 (B7-H3)	CNS/Leptomeningeal Tumor from Neuroblastoma (BTD, ODD and RPDD)	75% Complete
Burtomab 131I-8H9 (B7-H3)	Desmoplastic Small Round Cell Tumor	75% Complete
Burtomab 124I-8H9 (B7-H3)	Diffuse Intrinsic Pontine Glioma (RPDD)	75% Complete
Burtomab-ADC (B7-H3)	B7-H3 positive LM tumors (Adult)	75% Complete
hu8H9 (B7-H3)	Solid Tumors (Adult)	75% Complete
hu3F8 (GD2)	Refractory/Relapsed Neuroblastoma (ODD)	75% Complete
hu3F8 (GD2)	Osteosarcoma (Pediatric) (ODD)	75% Complete
hu3F8-BsAb (GD2xCD3)	GD2 positive solid tumors (Adult)	75% Complete
hu3F8-BsAb (GD2xCD3)	Refractory Neuroblastoma and Ewing's Sarcoma (Pediatric)	75% Complete

BTD (Breakthrough Therapy Designation), ODD (Orphan Drug Designation) and RPDD (Rare Pediatric Disease Designation)

Overview

Y-mAbs Therapeutics, Inc (YmAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement. YmAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. YmAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.

Mission

YmAbs mission is to discover, develop and deliver novel antibody therapeutics for the treatment of both pediatric and adult cancer patients.

Company Highlights

YmAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer
Memorial Sloan Kettering Cancer Center, the world’s largest and oldest private cancer institution, is YmAbs’ scientific collaboration partner and shareholder
From MSK, YmAbs has exclusive global rights to two clinical stage antibody programs with a strong validated clinical safety profile, treating more than 1,000 neuroblastoma patients. These programs are today used as “standard-of-care” treatment for patients at Memorial Sloan Kettering Cancer Center
Further, YmAbs has licensed a protein Multimerization Technology Platform – MULTI TAG™, incubated and developed at MSK to further enhance the therapeutic effect of antibodies
Several ongoing clinical trials significantly improve survival rates for critical unmet medical needs among cancer patients
YmAbs has a management team with proven track record and antibody drug development experience as well as expertise in running leading public biopharmaceutical companies